Michael Barnett
A5083946982- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Advanced Neuroimaging Techniques and Applications
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Autoimmune and Inflammatory Disorders Research
- Advanced MRI Techniques and Applications
- Systemic Sclerosis and Related Diseases
- Immunotherapy and Immune Responses
- Ocular Diseases and Behçet’s Syndrome
- Hereditary Neurological Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Retinal and Optic Conditions
- Ultrasound Imaging and Elastography
- Radiomics and Machine Learning in Medical Imaging
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Functional Brain Connectivity Studies
- Glaucoma and retinal disorders
- Cerebral Venous Sinus Thrombosis
- Brain Tumor Detection and Classification
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Vasculitis and related conditions
The University of Sydney
2016-2025
Cooperative Trials Group for Neuro-Oncology
2016-2025
Royal Prince Alfred Hospital
2016-2025
Mind Australia
2015-2025
Teva Pharmaceuticals (Australia)
2024
Novartis (Australia)
2024
Central Adelaide Local Health Network
2024
Women's and Children's Health Network
2024
Griffith University
2020-2023
The University of Queensland
2023
Abstract The study describes the clinical and pathological findings in 12 patients with relapsing remitting multiple sclerosis, who died during or shortly after onset of a relapse. Pathological changes not previously associated formation new symptomatic lesions were observed seven cases, namely, extensive oligodendrocyte apoptosis microglial activation myelinated tissue containing few no lymphocytes myelin phagocytes. No current laboratory model particular, experimental allergic...
Classical paraneoplastic encephalitis syndromes with 'onconeural' antibodies directed to intracellular antigens, and the recently described or non-paraneoplastic encephalitides against both neural surface antigens (voltage-gated potassium channel-complexes, N-methyl-d-aspartate receptors) (glutamic acid decarboxylase-65), constitute an increasingly recognized group of immune-mediated brain diseases. Evidence for specific immune mechanisms, however, is scarce. Here, we report qualitative...
Objective We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination. Methods evaluated phenotypes, annualised relapse rates (ARR) prior on immunotherapy Expanded Disability Status Scale (EDSS), 218 demyelinating episodes from 33 paediatric 26 adult patients. Results The most common initial presentation cohort was optic neuritis (ON) 54% (bilateral (BON) 32%, unilateral (UON) 22%),...
Abstract Twenty‐three plaques obtained at early autopsy from 2 patients with secondary‐progressive multiple sclerosis were examined immunohistochemically for microglia/macrophages, and immunoglobulins components of activated complement. Most the lesions in both cases exhibited evidence low‐grade active demyelination an unusual type (frustrated phagocytosis) periplaque white matter. This included linear groups microglia engaging short segments disrupted myelin that associated deposits C3d,...
CD4 T-cell-dependent macrophage activation directed against a myelin or oligodendrocyte antigen is generally thought to be the mechanism causing destruction in multiple sclerosis (MS). However, areas within expanding MS lesions may exhibit prominent loss and apoptosis absence of infiltrating lymphocytes. The present study was designed further investigate inflammatory profile different regions rapidly lesions.Twenty-six active from 11 patients with early were serially sectioned immunostained...
A number of studies have been conducted with the onset secondary progressive multiple sclerosis as an inclusion criterion or outcome interest. However, a standardized objective definition has lacking. The aim this work was to evaluate accuracy and feasibility for sclerosis, enable comparability future research studies. Using MSBase, large, prospectively acquired, global cohort study, we analysed 576 data-derived definitions first compared these consensus opinion three neurologists. All were...
Background: Recognizing the cause of optic neuritis (ON) affects treatment decisions and visual outcomes. Objective: We aimed to define radiological features first-episode demyelinating ON. Methods: performed blinded assessment 50 patients presenting with myelin oligodendrocyte glycoprotein (MOG) antibody-associated ON (MOG-ON; n=19), aquaporin-4 (AQP4) (AQP4-ON; n=11), multiple sclerosis (MS)-associated (MS-ON; n=13), unclassified ( n=7). Results: Bilateral involvement was more common in...
Abstract Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). There currently no single definitive test for MS. Circulating exosomes represent promising candidate biomarkers host human diseases. Exosomes contain RNA, DNA, and proteins, can cross blood-brain barrier, are secreted from almost all cell types including cells CNS. We hypothesized that serum exosomal miRNAs could present useful blood-based assay MS detection monitoring....
We examined a cohort of adults with aquaporin-4 (AQP4) antibody-negative neuromyelitis optica/neuromyelitis optica spectrum disorder (NMO/NMOSD) for antibodies to myelin oligodendrocyte glycoprotein (MOG).We performed flow cytometry cell-based assay using live human lentivirus-transduced cells expressing full-length surface MOG. Serum was tested in 23 AQP4 NMO/NMOSD patients bilateral and/or recurrent optic neuritis (BON, n = 11), longitudinally extensive transverse myelitis (LETM, 10), and...
Prevention of irreversible disability is currently the most important goal disease modifying therapy for multiple sclerosis. The outcomes used in clinical trials rely on progression Expanded Disability Status Scale score confirmed over 3 or 6 months. However, sensitivity and stability this metric has not been extensively evaluated. Using global MSBase cohort study, we evaluated 48 criteria progression, testing three definitions baseline disability, two magnitude, long-term irreversibility...
CHAMPION-NMOSD (NCT04201262) is a phase 3, open-label, externally controlled interventional study evaluating the efficacy and safety of terminal complement inhibitor ravulizumab in adult patients with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab binds same component 5 epitope as approved therapeutic eculizumab but has longer half-life, enabling an extended dosing interval (8 vs 2 weeks).The availability precluded use concurrent...
Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS) relapses, which increase in the early postpartum period. Postpartum relapse risk has been predicted by pre-pregnancy disease activity some studies. Objective: To re-examine effect of on relapses using large international MSBase Registry, examining predictors relapse. Methods: An observational case–control study was performed including pregnancies post-MS onset. Annualised rate (ARR) and median Expanded...
The aim of this work was to evaluate sex differences in the incidence multiple sclerosis relapses; assess relationship between and primary progressive disease course; compare effects age duration on relapse incidence. Annualized rates were calculated using MSBase registry. Patients with incomplete data or <1 year follow-up excluded. only included ratio analysis. Relapse incidences over 40 years 70 compared females males Andersen-Gill Tweedie models. Female-to-male ratios stratified by annual...
Objective In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab fingolimod. However, no studies have directly compared the outcomes of switching these agents. Methods Using MSBase, a large international, observational, prospectively acquired cohort study, we identified relapsing–remitting experiencing relapses disability progression within 6 months immediately preceding...
Background Multiple Sclerosis is more common in women than men and females have relapses men. In a large international cohort we evaluated the effect of gender on disability accumulation disease progression to determine if male MS patients worse clinical outcome females. Methods Using MSBase Registry, data from 15,826 25 countries was analysed. Changes severity (EDSS) were compared between sexes using repeated measures analysis generalised linear mixed models. Kaplan-Meier used test for sex...
Abstract Objective To identify evidence of a discrete, specific immune response in multiple sclerosis (MS) by analyzing the distribution immunoglobulins and complement tissue derived from cases MS, control inflammatory white matter diseases known to express viral autoantigens brain spinal cord. Methods Autopsy 25 MS patients 24 with other neurological was examined immunohistochemically for activated (C3d C9neo). Results In remote focal lesions diseases, IgG detected many normal structures...